Journal
IMMUNOTHERAPY
Volume 6, Issue 5, Pages 611-621Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.14.36
Keywords
chimeric antigen receptor; Ewing sarcoma; NK cell; regulatory T cell; T-cell receptor; T-cell therapy; tumor antigen; tumor immune escape; tumor microenvironment
Categories
Ask authors/readers for more resources
Ewing sarcoma is a rare cancer of bone and soft tissues defined by a specific chromosomal rearrangement. Preclinical development of immunological treatment strategies includes expansion of T cells with native or grafted T-cell receptor specificities for Ewing sarcoma-associated intracellular antigens, and T-cell engineering with chimeric antigen receptors targeting surface antigens. In vitro preactivated NK cells may also have activity in this cancer. Major challenges are the heterogeneity of antigen expression in individual Ewing sarcomas, and the coexpression of most candidate targets on normal cells. Moreover, homing of therapeutic effector cells to both primary and metastatic tumor sites and adequate function within the immunosuppressive tumor microenvironment will have to be ensured to allow for effective immune targeting of this cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available